TABLE 3.
Concordance for clarithromycin results between GenoType HelicoDR and susceptibility testing for the H. pylori included in the phase 2 study
| Reference resultsa | GenoType HelicoDR result |
||
|---|---|---|---|
| n | Mutation alleleb | Wild-type allelec | |
| Strains (n = 92) | |||
| Cla resistant | 48 | 43 | 5d |
| Cla susceptible | 44 | 1e | 43 |
| Biopsy specimens (n = 105) | |||
| Cla resistant | 49 | 48 | 1f |
| Cla susceptible | 56 | 0 | 56 |
| Total (n = 197) | |||
| Cla resistant | 97 | 91 | 6 |
| Cla susceptible | 100 | 1 | 99 |
a
Reference phenotype (Etest MIC using a breakpoint of 0.5 μg/ml).
b
At least one of the following mutation bands: 23S-MUT1, 23S-MUT2, or 23S-MUT3.
c
Presence of the 23S-WT band and no 23S mutation band.
d
For three strains and one biopsy specimen, a mixture of wild-type and resistant populations was assessed; for the two remaining strains, the clarithromycin MICs were 6 and 24 μg/ml, respectively.
e
A MIC of 0.016 μg/ml and a double-genotype population were assessed by real-time PCR.
f
Clarithromycin MIC of 1 μg/ml.